(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 4. Reduction of dfna5 activity leads to abnormal ear and cartilage
development. (A-C) Lateral views of wild-type (A), 15 ng dfna5
ATG-MO-injected (B) and 25 ng dfna5 ATGMO-injected (C) embryos,
indicating a dose-dependent malformation of the lower jaw (arrows). (D,E)
Dorsal view of wild-type (D) and 20 ng dfna5 ATG-MO-injected (E) embryos at
day 5, showing malformation of the anterior and posterior column in the
morphant ear (arrows). (F,G) Close up of the right ear in D and E,
respectively. (G) The anterior column (ac, arrow) of the morphant is
malformed, the posterior column (pc, large arrows) is interrupted. (H-J)
Lateral view of the ear at day 5 (anterior towards the left, ventral towards
the bottom) of wild type (H), 15 ng dfna5 ATG-MO injected (I) and 25
ng dfna5 ATG-MO injected (J) embryos. In morphants, either one or
more columns do not fuse (arrows), depending on the injected dose of
dfna5 ATGMO. ao, anterior otolith; po, posterior otolith. Scale bar:
300 µm in A-C; 250 µm in D,E; 80 µm in F,G; 125 µm in HJ. ac,
anterior column; pc, posterior column.